Director Dealing

RNS Number : 1343X
Destiny Pharma PLC
30 April 2021
 

Destiny Pharma plc

("Destiny Pharma" or the "Company")

Director Dealing

Destiny Pharma plc (AIM: DEST) a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life threatening infections, announces that it was notified on 29 April 2021 that on that same day, Nick Rodgers, Chairman of the Company, purchased 1,511 Ordinary Shares at a price of 148.7p per Ordinary Share. Following the transaction his total beneficial interest is 53,973 Ordinary Shares, representing 0.09% of the total issued share capital of the Company.

The above purchase of shares is pursuant to the award of a 2020 bonus to Mr. Rodgers, payable in Destiny Pharma shares (on a net of tax basis).  The bonus is payable in two equal tranches following the announcement of the Company' 2020 annual results and 2021 interim results.

Details of the full notification received by the Company are set out below:

 

1. 

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Nick Rodgers

2. 

Reason for the Notification

a)

Position/status

Chairman

b)

Initial notification/Amendment

Initial notification

3. 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Destiny Pharma plc

b)

LEI

213800O9WH9Z38EHAC95

4. 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

Ordinary Shares of 1 pence each in Destiny Pharma Plc

Identification code

DEST    GB00BDHSP575

b)

Nature of the transaction

Purchase of Ordinary Shares

c)

Price(s) and volume(s)

148.7 pence per Ordinary Share

1,511 Ordinary Shares

d)

Aggregated information:

Aggregated volume

Price

 

See 4c) above 

 

e)

Date of the transaction

29 April 2021

f)

Place of the transaction

London Stock Exchange, AIM Market

 

Enquiries:

Destiny Pharma plc

+44 (0) 1273 704 440

Neil Clark (Chief Executive Officer)
Shaun Claydon (Chief Financial Officer and Company Secretary)


finnCap Limited - Nominated Adviser and Joint Broker

+44 (0) 20 7220 0500

Geoff Nash / Kate Bannatyne / Charlie Beeson (Corporate Finance)
Alice Lane (ECM)


WG Partners LLP - Joint Broker

+44 (0) 20 3705 9330

Nigel Barnes / Claes Spång / Nigel Birks / Andrew Craig


Optimum Strategic Communications

+44 (0) 203 174 1789

Mary Clark / Shabnam Bashir / Manel Mateus

 

 


The information communicated in this announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014.

About Destiny Pharma

Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which is in a Phase 2b clinical trial targeting the prevention of post-surgical Staphylococcal hospital including MRSA. It is also co-developing SPOR-COV, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XF research projects.

 

For further information, please visit  https://www.destinypharma.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHFLFLRSRIAFIL
UK 100

Latest directors dealings